Welcome to our dedicated page for MAIA Biotechnology SEC filings (Ticker: MAIA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MAIA Biotechnology, Inc. filings document the regulatory record for a clinical-stage oncology company developing ateganosine for non-small cell lung cancer. Form 8-K reports cover THIO-101 clinical updates, oncology conference materials, shareholder communications on the development pipeline, FDA Fast Track disclosure, and forward-looking risk language tied to investigational drug development.
The company’s filings also document capital structure and governance matters, including an underwritten common stock offering conducted under an effective Form S-3 shelf registration, the related underwriting agreement and use-of-proceeds disclosure, executive compensation actions, and annual meeting proxy matters such as director elections and auditor ratification.
MAIA Biotechnology, Inc. reported results of its 2026 annual shareholder meeting. As of the March 23, 2026 record date, 60,671,491 common shares were outstanding and entitled to vote, and 37,547,754 shares were present in person or by proxy, representing approximately 61.88%, so a quorum was reached.
Stockholders re-elected Class I directors Louie Ngar Yee and Steven Chaouki to three-year terms expiring at the 2029 annual meeting or until their successors are elected and qualified. Votes for Louie Ngar Yee were 16,658,677 for and 8,796,832 withheld, with 11,375,414 broker non-votes. Votes for Steven Chaouki were 25,109,811 for and 345,698 withheld, with 11,375,414 broker non-votes.
Shareholders also ratified the appointment of Grant Thornton LLP as independent registered public accounting firm for the year ending December 31, 2026, with 37,278,294 votes for, 210,408 against, and 19,052 abstentions.
MAIA Biotechnology, Inc. Schedule 13G discloses that Solas Capital Management, LLC and Frederick Tucker Golden report shared beneficial ownership of 4,297,004 shares of common stock. The filing states this represents 7.1% of the class based on 60,671,491 shares outstanding as of March 23, 2026.
The filing states Solas acts as investment manager to a private fund and sub-adviser to another fund and that each fund disclaims beneficial ownership under Rule 13d-4; voting and dispositive power are reported as shared for the listed 4,297,004 shares.
MAIA Biotechnology, Inc. has suspended sales of its common stock under its At The Market Offering Agreement with H.C. Wainwright & Co. and has given notice to terminate the agreement effective seven business days after May 14, 2026.
Under a March 28, 2025 prospectus supplement for up to $11,200,000, the company offered and sold 3,116,012 shares of common stock, generating gross proceeds of approximately $5,680,924 before ending use of this at-the-market program.
MAIA Biotechnology, Inc. is amending its shelf to report termination of its at-the-market program covering up to $11,200,000 of common stock. The company reports that, since the prior prospectus dated March 28, 2025, it sold 3,116,012 shares for gross proceeds of $5,680,924 under the sales agreement with H.C. Wainwright & Co.
On May 14, 2026 MAIA suspended sales under the sales agreement and provided notice to terminate the agreement and the related at-the-market offering; termination becomes effective seven business days after May 14, 2026. The supplement also terminates the prior prospectuses on the same schedule. The last reported sale price on the NYSE American was $1.36 per share on May 14, 2026.
MAIA Biotechnology reported a larger net loss as it accelerated cancer drug development but significantly strengthened its balance sheet. For the three months ended March 31, 2026, net loss was $6.4 million versus $4.5 million a year earlier, driven by higher research and development and general and administrative costs.
Research and development expenses rose to $3.5 million, while general and administrative expenses increased to $3.4 million, reflecting expanded clinical activity and corporate infrastructure. Other income of $0.6 million included NIH grant income and a gain from remeasuring warrant liabilities.
Cash increased to $34.4 million from $8.7 million at year-end 2025, and working capital reached $29.0 million, mainly due to a March 2026 confidentially marketed public offering and follow-on that raised approximately $33 million gross. Management states these proceeds are expected to fully fund the pivotal Phase 3 trial of lead asset ateganosine (THIO) in non-small cell lung cancer.
Clinically, MAIA reported overall survival beyond two years for eight NSCLC patients in its Phase 2 THIO-101 trial, activated the first U.S. site in the study’s expansion, and continues planning Phase 2 programs in hepatocellular, colorectal, and small cell lung cancers.
MAIA Biotechnology reported a key clinical milestone for its lead cancer therapy ateganosine, a telomere-targeting drug being tested in advanced non-small cell lung cancer (NSCLC). The company activated the first U.S. site in its ongoing international Phase 2 THIO-101 expansion trial, with the initial location at Summit Medical Group in New Jersey and plans for four additional U.S. sites in 2026.
The third-line NSCLC evaluation in the U.S. is supported by a $2.3 million grant from the National Institutes of Health. The trial, which already has 44 active sites across six countries in Europe and Asia, is studying ateganosine both as monotherapy and in sequence with cemiplimab (Libtayo). MAIA highlights prior THIO-101 results showing disease control, response rates, and overall survival above standard-of-care benchmarks, including eight patients with overall survival beyond two years, while noting the regimen has shown an acceptable safety profile to date. Ateganosine holds FDA Fast Track designation for advanced NSCLC.
MAIA Biotechnology CEO Vitoc Vlad received a grant of 800,000 stock options as equity compensation. The options give him the right to buy 800,000 shares of common stock at an exercise price of $1.28 per share and expire on April 10, 2036.
The grant was made under MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan. The options vest over four years, with 25% vesting on the first anniversary of the April 10, 2026 grant date and the remaining 75% vesting in equal monthly installments over the following 36 months. After this grant, Vlad holds 800,000 options directly, and the filing shows no open-market stock purchases or sales.
MAIA Biotechnology’s Chief Scientific Officer Sergei Gryaznov received a grant of 400,000 stock options to acquire common shares at an exercise price of $1.28 per share. These options were granted under MAIA Biotechnology, Inc.’s 2021 Equity Incentive Plan as part of equity-based compensation.
The options vest over four years, with 25% vesting on the first anniversary of the April 10, 2026 grant date and the remaining options vesting in equal monthly installments over the following 36 months. After this grant, Gryaznov holds 400,000 stock options directly, according to the filing.
MAIA Biotechnology, Inc. reported that its Head of Finance, Jeffrey C. Himmelreich, received a grant of stock options covering 30,000 shares of common stock. The options have an exercise price of $1.28 per share and expire on April 10, 2036. They were granted under the company’s 2021 Equity Incentive Plan as a compensation award, not an open-market purchase. The options vest over four years, with 25% vesting on the first anniversary of the April 10, 2026 grant date and the remainder vesting monthly over the following 36 months, and represent Himmelreich’s full reported option position of 30,000 shares after this grant.
MAIA Biotechnology reports that net proceeds from its $33 million March 2026 public common stock offering are expected to fully fund its ongoing pivotal Phase 3 THIO-104 trial of ateganosine in third-line non-small cell lung cancer (NSCLC).
The FDA has granted ateganosine Fast Track designation in this setting. THIO-104 is a global, multicenter, open-label Phase 3 study comparing ateganosine sequenced with a checkpoint inhibitor against chemotherapy in a 1:1 randomization of up to 300 patients, using median overall survival and safety as primary objectives. Interim Phase 3 data are expected next year and may support discussions with the FDA about potential early full commercial approval in third-line NSCLC if results are consistent with prior Phase 2 data.